|
Market Closed -
NYSE
16:00:03 2026-09-10 EDT
|
5-day change | 1st Jan Change | ||
| 18.11 USD | -0.55% |
|
-1.74% | +16.16% |
| 09-09 | Takeda Publishes Phase 3 Data Demonstrating Oveporexton Improves Narcolepsy Type 1 Symptoms | CI |
| 09-08 | Pharvaris' genetic disorder drug meets main goal in late-stage trial | RE |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| TAKEDA PHARMACEUTICAL COMPANY LIMITED | Other Pharmaceuticals | -0.55% | -1.74% | +16.16% | +18.60% | +6.65% | 58.38B |
-
|
-
|
-
|
Select your edition
All financial news and data tailored to specific country editions
